Portal de Periódicos da CAPES

Antenatal Screening for Fetomaternal Alloimmune Thrombocytopenia: Should we be doing it?

2002; Wiley; Volume: 83; Issue: s1 Linguagem: Inglês

10.1111/j.1423-0410.2002.tb05343.x

1423-0410

Michael Murphy, L. M. Williamson, S. J. Urbaniak,

Blood disorders and treatments

Vox SanguinisVolume 83, Issue s1 p. 409-416 Antenatal Screening for Fetomaternal Alloimmune Thrombocytopenia: Should we be doing it? M.F. Murphy, Corresponding Author M.F. Murphy National Blood Service, Department of Haematology, John Radcliffe Hospital, and University of Oxford,M.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this authorL.M. Williamson, Corresponding Author L.M. Williamson National Blood Service and Division of Transfusion Medicine, University of Cambridge, andM.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this authorS.J. Urbaniak, Corresponding Author S.J. Urbaniak Scottish National Blood Transfusion Service and University of AberdeenM.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this author M.F. Murphy, Corresponding Author M.F. Murphy National Blood Service, Department of Haematology, John Radcliffe Hospital, and University of Oxford,M.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this authorL.M. Williamson, Corresponding Author L.M. Williamson National Blood Service and Division of Transfusion Medicine, University of Cambridge, andM.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this authorS.J. Urbaniak, Corresponding Author S.J. Urbaniak Scottish National Blood Transfusion Service and University of AberdeenM.F. Murphy. L.M. Williamson & S.J. Urbaniak National Blood Service, Department of Haematology. John Radcliffe Hospital and University of Oxford National Blood Service and Division of Transfusion Medicine, University of Cambridge, and Scottish National Blood Transfusion Service and University of Aberdeen. E-mail. [email protected]Search for more papers by this author First published: 11 February 2011 https://doi.org/10.1111/j.1423-0410.2002.tb05343.xCitations: 39Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES Bessos H., Mirza S., McGill A., Williamson L.M., Hadfield R., & Murphy W.G. (1996) A whole blood assay for platelet HPA-1 phenotyping applicable to large scale antenatal screening. British Journal of Haematology, 92, 221—225. Bessos H., Hofner M., Salamat A., Wilson D., Urbaniak S., & Turner M.L. (1999) An international trial demonstrates suitability of a newly developed whole-blood ELISA kit for multicentre platelet HPA-a phenotyping. Vox Sanguinis, 77, 103—106. Bessos H., Fagge T., Thomson A., Wilson D., Harkness M., Rentoul F., Ahya R., Urbaniak S., & Turner M.L. (2002) Neonatal alloimmune thrombocytopenia in Scotland: a national HPA-1a epidemiological study involving 26,506 pregnant women. 7th European Symposium on Platelet, Granulocyte and Red Cell Immunobiology, Belgirate. Birchali J.E, Murphy M.F, Kaplan C., & Kroll H., on behalf of the European FMAIT Study Group. (2000) European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Transfusion Medicine, 10, 328. Blanchette V.S., Chen L., de Friedberg Z S., Hogan V.A., Trudel E., & Decary F. (1990) Alloimmunization to the PIAI antigen: results of a prospective study. British Journal of Haematology, 74, 209—215. Bowman J., Harman C., Mentigolou S., & Pollock J.. (1992) Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet, 340, 1034—1035. British Committee for Standards in Haematology. (1996) Guidelines for blood grouping and red cell antibody testing during pregnancy. Transfusion Medicine, 6, 71—74. Burrows R.F. & Kelton J G. (1993) Fetal thrombocytopenia and its relation to maternal thrombocytopenia. New England Journal of Medicine, 329, 1463—1466. Bussel J.B., Zabusky M.R., Berkowitz R.L., & McFarland J.G. (1997) Fetal alloimmune thrombocytopenia. New England Journal of Medicine, 337, 22—26. Cairns J.. (1998) Economic evaluation and Health care. Nuffield Occasional Papers - Health Economics series, 7, 22—27. Consensus Conference on anti-D prophylaxis. (1998) British Journal of Obstetrics and Gynaecology, 105, suppl 18, 1–2. Davoren A., McParland P., Crowley J., Dolly E., O'Toole C.E., Barnes C.A., Kearney F., & Murphy W.G. The epidemiology of neonatal alloimmune thrombocytopenia due to HPA-1a mismatched pregnancies in Irelend (submitted for publication). Doughty H.A, Murphy M.F., Metcalfe P., & Waters A.H. (1995) Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. British Journal of Haematology, 90, 321—325. Dreyfus M., Kaplan C., Verdy E., Schlegel N., Durand-Zaleski I., Tchernia G., and the Immune Thrombocytopenia Working Group. (1997) Frequency of immune thrombocytopenia in newborns: a prospective study. Blood, 89, 4402—4406. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., Uzan S., Dreyfus M., & Kaplan C.. (1996). Screening primiparous women for fetal/neonatal alloimmune thrombocytopenia a prospective comparison of effectiveness and costs. American Journal of Perinatology 13, 423—431. Gafni A., & Blanchette V.S. (1988) Screening for neonatal alloimmune thrombocytopenia: an economic perspective. Current Studies in Haematology and Blood Transfusion, 54, 140—147. Garner S.F., Smethurst P.A, Meneux Y., Aeby C., Armour K L., Scott M.L, Williamson L.M., Metcalfe P., Goodall A., Clark M L., Rigal D., Schawaller M., & Ouwehand W H (2000) A one-stage whole blood HPA-1a phenotyping assay using a recombinant monoclonal IgGI anti-HPA-1a. Transfusion, 108, 440—447. Harrington, W.J., Sprague, C.C, Minnich, V., Moore C V, Aulvin R C., & Dubach R. (1953) Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura Annals of Internal Medicine, 38, 433—469. Husebekk A., Killie M K., Aune B., Oian P., Dahl L B., & Kristiansen I S (2002) Screening for anti-HPA-1a alloantibodies in almost 35,000 pregnancies. How are the babies doing? 7th European Symposium on Platelet. Granulocyte and Red Cell Immunobiology, Belgirate. Jaegtvik S., Husebekk A., Aune B., Oian P., Dahl L B., & Skogen B.. (2000) Neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies the level of maternal antibodies predicts the severity in the newborn British Journal of Obstetrics & Gynaecology, 107, 691—694. Kaplan C., Daffos F., Forestier F., Morel M C, Chesnel N., & Tchernia G. Current trends in neonatal alloimmune thrombocytopenia diagnosis and therapy In: C. Kaplan-Gouet, N. Schlegel, C H Salmon, J. McGregor, eds. Platelet Immunology; Fundamental and Clinical aspects Colloque Inserm. Paris John Libby Eurotext, 1991a. 206 267—278. Kaplan C., Morel-Kopp M.C, Kroll H., Kiefel V., Achlegel N., Chesnel N., & Mueller-Eckhardt C. (1991b) HPA-5b (Bra) neonatal alloimmune thrombocytopenia clinical and immunological analysis of 39 cases British Journal of Haematology, 78, 425—429. Kaplan C., Murphy M F, Kroll H., & Waters A.H (1998) Fetomaternal alloimmune thrombocytopenia, antenatal therapy with IVIgG and steroids - more questions than answers. British Journal of Haematology, 100, 62—65. Kiefel V., Santoso S., Weisheit M., & Mueller-Eckhardt C. (1987) Monoclonal antibody-specific immobilization of platelet antigens (MAIPA) a new tool for the identification of platelet-reactive antibodies Blood, 70, 1722—1726. Kroll H., Kiefel V., Giers G., Bald R., Hoch J., Hanfland P., Hansmann M., & Mueller-Eckhardt C. (1994) Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia Transfusion Medicine, 4, 293—296. L'Abbe D., Tremblay L., Goldman M., Decary F., & Chartrand P. (1992) Alloimmunization to platelet antigen HPA-1a (Zwa). association with HLA-DRw52a is not 100% Transfusion Medicine, 2, 251. Letsky EA, & Greaves M. (1996). Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. British Journal of Haematology, 95, 21—26. Lo Y.M.D, Hjelm M., Fidler C., Sargent I.L., Murphy M F, Chamberlain PF, Poon M.K.P., Redman C W G. & Wainscoat J S (1998) Non-invasive prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma New England Journal of Medicine, 339, 1734—1738. Mackenzie F., Brennand J., Peterkin M., & Cameron A. (1999) Management of fetal alloimmune thrombocytopenia - a less invasive option?. Journal of Obstetrics & Gynaecology, 19, 119—121. Maslanka K., Guz K., Wlodarczyk B., Rumas-Bec J., Ziarko S., Debski R., Uhrynowska M., & Zupanska B. (2002) Antenatal screening of unselected pregnant women for HPA-1a antigen, anti-HPA-1a antibody and evaluation of alloimmune thrombocytopenia 7th European Symposium on Platelet. Granulocyte and Red Cell Immunobiology, Belgirate. Metcalfe P., Doughty H.A, Murphy M F, & Waters A.H (1994) A simplified method for large-scale HPA-1a phenotyping for antenatal screening Transfusion Medicine, 4, 21—24. Metcalfe P., Allen D., Chapman J., & Ouwehand W H (1997) Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens British Journal of Haematology, 97, 204—207. Mueller-Eckhardt C., Mueller-Eckhardt G., Willen-Ohff H., Horz A., Kuenzlen E., O'Neill G J, & Schendel D.J. (1985) Immunogenicity of and immune response to the human platelet antigen Zw is strongly associated with HLA-B8 and DR3 Tissue Antigens, 26, 71—76. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., Mueller-Eckhardt G., & Santoso S. (1989) 348 cases of suspected neonatal alloimmune neonatal thrombocytopenia Lancet, 1, 363—366. Murphy M.F, Waters A.H, Doughty H A, Hambley H., Mibashan R S, Nicolaides K.H., & Rodeck C H. (1994) Antenatal management of fetal alloimmune thrombocytopenia report of 15 affected pregnancies. Transfusion Medicine, 4, 281—292. Murphy M.F, Hambley H., Nicolaides K., & Waters A H (1996) Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus Prenatal Diagnosis, 16, 1152—1155. Murphy M.F, Kaplan C., & Kroll H. (1998) Fetomaternal alloimmune thrombocytopenia antenatal therapy with IVIgG and steroids British Journal of Haematology, 102, 1380—1385. Murphy M.F, Verjee S., & Greaves M. (1999) Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia British Journal of Haematology, 105, 123—126. Murphy M.F., & Williamson L.M. (2000) Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK National Screening Committee. British Journal of Haematology, 111, 726—732. Overton T.G., Duncan K.R., Jolly M., Letsky E., & Fisk NM.. (2002) Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. American Journal of Obstetrics and Gynecology, 186, 826—831. Paidas M.J., Berkowitz R.L., Lynch L., Lockwood C.J., Lapinski R., McFarland J.G., & Bussel J.B. (1995) Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. American Journal of Obstetrics and Gynecology, 172, 475—479. Radder C.M., Brand A., & Kanhai H.H.H. (2001) A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. American Journal of Obstetrics & Gynecology. 185, 683—688. Ranasinghe E., Walton J.D., Hurd C.M., Saul L., Smith G., Campbell K., & Ouwehand W.H. (2001) Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. British Journal of Haematology, 113, 40—42. Ranasinghe E., Campbell K., Walton J., Hurd C., Ouwehand W.H., & Smith G.. (2002) Foetomaternal alloimmune thrombocytopenia in London and the South East of England: a study of 130 alloimmunized pregnancies. 7th European Symposium on Platelet, Granulocyte and Red Cell Immunobiology, Belgirate. Sainio S., Teramo K., & Kekomaki R.. (1999) Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfusion Medicine, 9, 321—330. Spencer J.A., & Burrows R.F. (2001) Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 41, 45—55. Torrance G.W., & Zipursky A., (1984). Cost-effectiveness of antepartum prevention of Rh immunization. Clinics in Perinatology, 11, 267—281. Vaughan J.I., Manning M., Warwick R.M., Letsky E.A., Murray N.A. & Roberts I.A.G. (1998) Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. New England Journal of Medicine, 338, 798—803. Warwick R.M., Vaughan J., Murray N., Lubenko A., & Roberts I.. (1994) In vitro culture of colony forming unit-megakaryocyte (CFU-MK) in fetal alloimmune thrombocytopenia. British Journal of Haematology, 88, 874—877. Watkins N.A., Armour K.L., Smethurst P.A., Metcalfe P., Scott M.L., Hughes D.L., Smith G.A., Williamson L.M., Clark M.R., & Ouwehand W.H. (1999) Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgGI-based assays. Transfusion, 39, 781—789. Williamson L.M., Hackett G., Rennie J., Palmer C., Maciver C., Hadfield R., Hughes D., Jobson S., & Ouwehand W.H. (1998) The natural history of fetomaternal alloimmunisation to the platelet-specific antigen HPA-1a as determined by antenatal screening. Blood, 92, 2280—2287. Zimmerman R., & Huch A.. (1992) In-utero fetal therapy with immunoglobulin for alloimmune thrombocytopenia. Lancet, 340, 606. Citing Literature Volume83, Issues1August 2002Pages 409-416 ReferencesRelatedInformation